+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Arthritis Monoclonal Antibodies Global Market Report 2022: By Drug, By Application, By End-Use

  • PDF Icon

    Report

  • 400 Pages
  • March 2022
  • Region: Global
  • The Business Research Company
  • ID: 5553731
Arthritis Monoclonal Antibodies Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global arthritis monoclonal antibodies (mab's) market.



This report focuses on arthritis monoclonal antibodies (mab's) market which is experiencing strong growth. The report gives a guide to the arthritis monoclonal antibodies (mab's) market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase


  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates
  • Create regional and country strategies on the basis of local data and analysis
  • Identify growth segments for investment
  • Outperform competitors using forecast data and the drivers and trends shaping the market
  • Understand customers based on the latest market research findings
  • Benchmark performance against key competitors
  • Utilize the relationships between key data sets for superior strategizing
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:


Where is the largest and fastest growing market for the arthritis monoclonal antibodies (mab's)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Arthritis Monoclonal Antibodies (mab's) market global report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider arthritis monoclonal antibodies (mab's) market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth
  • Market segmentations break down market into sub markets
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers
  • The arthritis monoclonal antibodies (mab's) market section of the report gives context. It compares the arthritis monoclonal antibodies (mab's) market with other segments of the arthritis monoclonal antibodies (mab's) market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, arthritis monoclonal antibodies (mab's) indicators comparison

Scope


Markets Covered:


1) By Drug: Remicade; Humira; Enbrel; Rituxan; Orencia; Actemra; Simponi; Cimzia; Remsima
2) By Application: Rheumatoid Arthritis; Osteoarthritis; Psoriatic Arthritis; Ankylosing Spondylitis; Fibromyalgia; Others
3) By End-Use: Hospitals; Research Institutes; Others

Companies Mentioned: Johnson & Johnson; Roche; Novartis; Pfizer Inc.; AbbVie Inc

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes

Table of Contents

1. Executive Summary2. Arthritis Monoclonal Antibodies Market Characteristics3. Arthritis Monoclonal Antibodies Market Trends And Strategies4. Impact Of COVID-19 On Arthritis Monoclonal Antibodies
5. Arthritis Monoclonal Antibodies Market Size And Growth
5.1. Global Arthritis Monoclonal Antibodies Historic Market, 2016-2021, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Arthritis Monoclonal Antibodies Forecast Market, 2021-2026F, 2031F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Arthritis Monoclonal Antibodies Market Segmentation
6.1. Global Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Remicade
  • Humira
  • Enbrel
  • Rituxan
  • Orencia
  • Actemra
  • Simponi
  • Cimzia
  • Remsima
6.2. Global Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Rheumatoid Arthritis
  • Osteoarthritis
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Fibromyalgia
  • Others
6.3. Global Arthritis Monoclonal Antibodies Market, Segmentation By End-use, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Hospitals
  • Research Institutes
  • Others

7. Arthritis Monoclonal Antibodies Market Regional And Country Analysis
7.1. Global Arthritis Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
7.2. Global Arthritis Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8. Asia-Pacific Arthritis Monoclonal Antibodies Market
8.1. Asia-Pacific Arthritis Monoclonal Antibodies Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8.3. Asia-Pacific Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
9. China Arthritis Monoclonal Antibodies Market
9.1. China Arthritis Monoclonal Antibodies Market Overview
9.2. China Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
9.3. China Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
10. India Arthritis Monoclonal Antibodies Market
10.1. India Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
10.2. India Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11. Japan Arthritis Monoclonal Antibodies Market
11.1. Japan Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11.2. Japan Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12. Australia Arthritis Monoclonal Antibodies Market
12.1. Australia Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12.2. Australia Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13. Indonesia Arthritis Monoclonal Antibodies Market
13.1. Indonesia Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13.2. Indonesia Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14. South Korea Arthritis Monoclonal Antibodies Market
14.1. South Korea Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14.2. South Korea Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15. Western Europe Arthritis Monoclonal Antibodies Market
15.1. Western Europe Arthritis Monoclonal Antibodies Market Overview
15.2. Western Europe Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15.3. Western Europe Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16. UK Arthritis Monoclonal Antibodies Market
16.1. UK Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16.2. UK Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17. Germany Arthritis Monoclonal Antibodies Market
17.1. Germany Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17.2. Germany Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18. France Arthritis Monoclonal Antibodies Market
18.4. France Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18.5. France Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19. Eastern Europe Arthritis Monoclonal Antibodies Market
19.1. Eastern Europe Arthritis Monoclonal Antibodies Market Overview
19.2. Eastern Europe Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19.3. Eastern Europe Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20. Russia Arthritis Monoclonal Antibodies Market
20.1. Russia Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20.2. Russia Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21. North America Arthritis Monoclonal Antibodies Market
21.1. North America Arthritis Monoclonal Antibodies Market Overview
21.2. North America Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21.3. North America Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22. USA Arthritis Monoclonal Antibodies Market
22.1. USA Arthritis Monoclonal Antibodies Market Overview
22.2. USA Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22.3. USA Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23. South America Arthritis Monoclonal Antibodies Market
23.1. South America Arthritis Monoclonal Antibodies Market Overview
23.2. South America Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23.3. South America Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24. Brazil Arthritis Monoclonal Antibodies Market
24.1. Brazil Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24.2. Brazil Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25. Middle East Arthritis Monoclonal Antibodies Market
25.1. Middle East Arthritis Monoclonal Antibodies Market Overview
25.2. Middle East Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25.3. Middle East Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26. Africa Arthritis Monoclonal Antibodies Market
26.1. Africa Arthritis Monoclonal Antibodies Market Overview
26.2. Africa Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26.3. Africa Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
27. Arthritis Monoclonal Antibodies Market Competitive Landscape And Company Profiles
27.1. Arthritis Monoclonal Antibodies Market Competitive Landscape
27.2. Arthritis Monoclonal Antibodies Market Company Profiles
27.2.1. Johnson & Johnson
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Roche
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Novartis
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Pfizer Inc
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. AbbVie Inc.
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Arthritis Monoclonal Antibodies Pipeline Analysis29. Key Mergers And Acquisitions In The Arthritis Monoclonal Antibodies Market30. Arthritis Monoclonal Antibodies Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright And Disclaimer

Executive Summary

Major players in the arthritis monoclonal antibodies market are Johnson & Johnson, Roche, Novartis, Pfizer Inc., AbbVie Inc., Amgen Inc., Genentech, GSK, AstraZeneca PLC. and Mylan N.V.

The global arthritis monoclonal antibodies market is expected to grow from $44.14 billion in 2021 to $49.44 billion in 2022 at a compound annual growth rate (CAGR) of 12.07.3%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $66.45 billion in 2026 at a CAGR of 7.7%.

The arthritis monoclonal antibodies market consists of sales of monoclonal antibodies used for the treatment of arthritis diseases. Arthritis is referred to as the joint pain that is characterized by inflammation, tenderness, pain and stiffness in and around the joints. Different monoclonal antibody drugs are used for the treatment of arthritis. These include infliximab, adalimumab and golimumab. The market consists of revenue generated by the company’s manufacturing monoclonal antibody drugs for arthritis by the sales of these products.

The main types of drugs in arthritis monoclonal antibodies are remicade, humira, enbrel, rituxan, orencia, actemra, simponi, cimzia and remsima. REMICADE is a prescription drug for persons with slightly to severely active Crohn's disease who haven't had success with other treatments. The different applications include rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, others and involves various sectors such as hopitals, research institutes, others.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The increasing prevalence of arthritis globally has contributed to the growth of the arthritis monoclonal antibody market. According to the Centre for Disease Control and Prevention (CDC), in 2020, the adult percentage of arthritis is 23% in USA which varies by country and osteoarthritis is the most common form of arthritis followed by gout, fibromyalgia and rheumatoid arthritis. According to WHO, the prevalence of rheumatoid arthritis varies between 0.3% and 1% and the worldwide estimates of osteoarthritis include 9.6% men and 18% women. The increased prevalence of arthritis and thee demand for personalized medicine is increasing the demand for the arthritis monoclonal antibody market.

The high cost of monoclonal antibodies is expected to hamper the global arthritis monoclonal antibody market. According to the American Journal of Managed Care (AJMC), a survey was conducted to know the average price of monoclonal antibodies approved in the last 20 years by the FDA across disease states and found that the average annual price of 1-year treatment for each monoclonal antibody indication was $96,731. The high costs of these antibodies are basically due to the cost incurred in development and production. High costs of monoclonal antibodies are therefore expected to limit the market growth.

The development of therapeutic monoclonal antibody products is becoming an indispensable tool in the development of the arthritis monoclonal antibody market. Monoclonal antibodies are more efficient than small molecules and peptides in the treatment of arthritis. These are target specific and has good efficiency for disease treatment. These improved treatment options are evident with the launch of a greater number of monoclonal antibody drugs for arthritis.

In May 2020, AbbVie acquired Allergan for $63 billion. AbbVie is a global biopharmaceutical company whose key therapeutic areas include Immunology and Neuroscience. It is now significantly expanding its revenue base and maintaining its position in immunology by acquiring Allergan. Allergan is a global pharmaceutical leader that manufactures devices, biologics, surgical and regenerative medicinal products all across the world.

The countries covered in the arthritis monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Johnson & Johnson
  • Roche
  • Novartis
  • Pfizer inc.
  • AbbVie inc.
  • Amgen inc.
  • Genentech
  • GSK
  • AstraZeneca plc.
  • Mylan N.V.
  • Bristol Myers Squibb
  • Eli Lily and Company
  • Thermofischer Scientific
  • Sanofi
  • Novo Nordisk A/S
  • Daiichi Sankyo Company ltd.
  • Seattle genetics
  • Teva pharmaceutical industries
  • Shanghi Junsi bioscience ltd.
  • GenScript
  • Sigma-Aldrich Co. LLC
  • AbGenomics
  • ADC Therapeutics
  • Agensys
  • Alexion Pharmaceuticals
  • ALMAC Group
  • Ambrx
  • Astellas Pharma
  • Celgene
  • Celldex Therapeutics

Methodology

Loading
LOADING...